Tango Therapeutics, Inc. TNGX

24.92 0.29 1.18% as of 25 Sep
Market cap
$4.2B
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 — —
P/S ratio
16.50 8.02 25.84 25.82 18.34 0.00 — —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 — —
P/Operating CF
(34.63) (9.21) (34.36) (22.71) (40.20) (1,027.12) — —
P/B ratio
2.97 1.69 3.73 2.57 1.97 1.51 — —
EV/Sales
10.99 1.89 16.59 11.07 5.23 0.00 — —
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 — —
EV/FCF
(4.90) (0.60) (5.07) (2.36) (3.16) 0.00 — —
Current Ratio
16.32 6.98 7.54 6.76 12.10 4.73 — —
Net Debt/EBITDA
3.08 1.75 2.93 3.35 8.48 3.70 — —
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 — —
ROE
(37.23%) (57.58%) (40.49%) (36.41%) (30.38%) (20.50%) — —
ROA
(28.41%) (36.24%) (24.25%) (23.10%) (16.46%) (50.15%) 0.00% —
ROIC
(2,661.91%) 0.00% 0.00% 0.00% 0.00% 0.00% — —
Return on Tangible Assets
(29.97%) (55.15%) (32.77%) (32.72%) (12.76%) (33.20%) — —
Average Days of Receivables
0.00 0.00 0.00 29.36 19.71 95.35 — —
Earnings Yield
(9.71%) (39.16%) (11.02%) (16.83%) (8.58%) 0.00% — —
Free Cash Flow Yield
(13.60%) (39.19%) (12.66%) (18.19%) (9.03%) 0.00% — —
Free Cash Flow per Share
(1.20) (1.21) (1.26) (1.33) (0.99) 2.16 — —
Book value per Share
2.98 1.83 2.68 2.84 5.55 1.21 — —
Free Cash Flow
(139.93) (132.25) (119.51) (116.77) (61.36) 68.97 — —
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 — —
Other line items

Show all line items

Columns are period end dates